Thanks for your opinion, but I think LP has a track record of solid business acumen and integrity. She is also holding a lot of shares.
The CEO of Northwest Biotherapeutics has worked for the U.S. government, was the managing director of a capital fund, and is a Harvard lawyer, so I am sure that she understands how to navigate these waters.
Her experience includes a presidential appointment to the U.S. Commerce Department many years ago. She also taught a course at the U.S. National Institutes of Health on the development and commercialization of medical products.
Advent an nwbo may happen but who can stomach tge thought of LP stuffing her pockets with more shareholders $
Standard bear narrative: Generalized statement with no details that points the finger at management. For some reason the bear narrative wants shareholders to turn against rhe management they just voted in favor of at the ASM, the management that succeeded where 400+ other management teams failed and the management that plans multiple RA submissions in 2023.